Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2016

Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2016
Published Oct 12, 2016
50 pages — Published Oct 12, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2016, provides in depth analysis on Glucagon Like Peptide 2 Receptor (GLP2R) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
- The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)
- Identify the use of drugs for target identification and drug repurposing
- Ide

  
Source:
Document ID
GMDHC0577TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Glucagon Like Peptide 2 Receptor (GLP2R) Overview61
Therapeutics Development73
  Glucagon Like Peptide 2 Receptor (GLP2R) Products under Development by Stage of Development71
  Glucagon Like Peptide 2 Receptor (GLP2R) Products under Development by Therapy Area81
  Glucagon Like Peptide 2 Receptor (GLP2R) Products under Development by Indication91
Glucagon Like Peptide 2 Receptor (GLP2R) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Glucagon Like Peptide 2 Receptor (GLP2R) Products under Development by Companies122
Glucagon Like Peptide 2 Receptor (GLP2R) Therapeutics Assessment145
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration161
  Assessment by Molecule Type172
Glucagon Like Peptide 2 Receptor (GLP2R) Companies Involved in Therapeutics Development194
  Naia Limited191
  Shire Plc201
  Tasly Pharmaceutical Group Co., Ltd.211
  Zealand Pharma A/S221
Glucagon Like Peptide 2 Receptor (GLP2R) Drug Profiles2312
  FE-203799 Drug Profile231
  glepaglutide Drug Profile242
  GXG-8 Drug Profile261
  NB-1002 Drug Profile271
  teduglutide Drug Profile285
  ZPGG-23 Drug Profile331
  ZPGG-72 Drug Profile341
Glucagon Like Peptide 2 Receptor (GLP2R) Dormant Projects351
Glucagon Like Peptide 2 Receptor (GLP2R) Featured News &Press Releases3613
  Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)361
  May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome371
  Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016381
  Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome381
  Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX391
  Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan391
  Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data401
  Jun 17, 2014: Zealand presented new data on GLP-1/GLP-2 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association s (ADA) 74th Scientific Sessions411
  Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome411
  Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection421
  Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome431
  Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting441
  Jan 30, 2013: New Peer-reviewed Publication Offers Guidance For Integrating Gattex For Injection Into Management Of Short Bowel Syndrome452
  Jan 02, 2013: ThriveRx Receives Limited Distribution Rights To NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome In Adults471
  Dec 27, 2012: Coram Specialty Infusion Services To Provide NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome472
Appendix492
  Methodology491
  Coverage491
  Secondary Research491
  Primary Research491
  Expert Panel Validation491
  Contact Us491
  Disclaimer501

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2016" Oct 12, 2016. Alacra Store. May 05, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Glucagon-Like-Peptide-2-Receptor-GLP2R-Pipeline-Review-H2-2016-2088-16796>
  
APA:
Global Markets Direct - Market Research. (2016). Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2016 Oct 12, 2016. New York, NY: Alacra Store. Retrieved May 05, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Glucagon-Like-Peptide-2-Receptor-GLP2R-Pipeline-Review-H2-2016-2088-16796>
  
US$ 3,500.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.